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EvaluaEon of Luminex-Based Multiplex Assays for CysEc Fibrosis 
Mutations 
C. King 1, T. McDevi l t  1, T. Yeomans 1, D.E. Barton 1; 
~NationaI Centre for Medical Genetics, am] 2Department of Medical Genetics, 
University College Dublbg Our Lady's Hospital f r SickChiMre~g Dublin, Irela~ul 
New technologies for mult iplex testing for single nucleotide polymorphisms are 
f inding applications in the diagnosis of genetic disorders. Plans for newborn 
screening for cystic fibrosis (CF) ha Ireland and issues of sensitivity and efficiency 
with our current "home brew" assay led us to look for a multiplexed CF assay 
which could be adapted to the mutation spectrum of the Irish population. We have 
an excellent knowledge of the Irish mutation spectrum, as all patients with 
mutations not detected by our ARMS assay are screened by DHPLC of the entire 
CFTR gene at the laboratory of Professor Claude Ferec ha Brest, France. 
We evaluated the CF Multicode Plx TM assay from Er aGen Biosciences, which tests 
for the CF mutations included ha the ACMGIACOG CF panel. Mult iCode uses an 
addit ional base pair constructed from the synthetic complementary bases 
isoguanosine (isoG) and 5' Me  isocytosine (isoC). Base pairing of isoG to isoC is 
highly specific. These additional bases are used in each step of the MultiCode 
process: PCR, extension labelling, mad liquid decoding on a Luminex instrument. 
Al l  steps are carried out in the same micro plate wel l  without ransfers or washings. 
We have taken the assay designed by Er aGen and designed target specific extension 
primers for 10 additional mutations which occur at a frequency of 0.15% or greater 
ha the Irish population. We have evaluated the core 29 target assay and the extended 
assay on a large cohort of samples of known genotype, to examine their sensitivity 
and specificity. We are also evaluating a second Luminex based assay, Signature 
CF TM from Ambion. Results of these studies, as wel l  as an analysis of cost and 
efficiency, wi l l  be presented. 
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A survey on CF neonatal screening prac6ce around Europe 
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The ECFS CF Neonatal Screening (NS) Working Group (WG) is aimed at 
connecting professionals working in CF NS, producing uidelines on critical issues, 
and helping European countries or regions interested in starting CF NS programs. 
About 70 people from various European countries take part in the WG. In order to 
achieve a comprehensive picture of the situation in Europe, and to detect fields ha 
need of standardization, a questionnaire was circulated to European CF NS services. 
The questionnaire was divided into various parts: NS protocol, sample collection 
(who collects, how and when), immtmoreactive tt3,psinogen (levels, centiles, when 
tested, how tested), genetic analysis (which mutations, techniques, informed 
consent issues), sweat test (suggested age, positive mad borderl ine values, 
techniques), diagnosis (diagNostic riteria, commtmication to the family), follow up 
(clinical protocols, segregation issues), data storing (infor matic tools, card storage), 
epidemiology (screened newborns, affected newboms, carriers, false positives, false 
negatives). Twenty four questionnaires were completed: 7 from the UK,  1 
(nationwide) from France, 12 from Italy, 1 from Spain, 1 (nationwide) from Austria, 
1 from Poland mad 1 from the Czech republic. These services have been working for 
an average of 11 years (range 9 months to 31 years), screen more than 1,600,000 
newborns per year, and every year detect more than 4120 affected neonates. Data 
evaluation is under way, and wi l l  be presented. 
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Procedures for Cystic Fibrosis (CF) announcement after neonatal 
screening: comparison between na6onal guidelines and results of an 
applied study 
L. Gu6ganton 1, G. Rault 1, S. Ravil ly 2 
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Neonatal screening of CF has been progressively generalized ha France since 2CO2. 
It allows early diagnosis mad an improvement in the medical follow up. However, 
the announcement of such a severe disease, usually asymptomatic at that time, 
raises the question of the optimal nnouncement pr ceedures ha this context. 
To answer this question, the fol lowing work was carried out consecutively: 
a research work evaluating the prceedures of CF announcement based on 
questionnaires given to parents and announcers; 
a pluridisciplinary workshop, resulting in published guidelines for announcing 
CF diagnosis after neonatal screening. 
We have compared the results of our research (announcement procedures before the 
publication of the guidelines) mad the guidelines (recommendations for the best 
announcement). 
The main divergences concern: 
announcers' training: the majority has not received specific training ha spite of 
recommendations; 
the fkst contact (by phone): announcer's should avoid suggesting, as far as 
possible, CF. Nevertheless, parents' opinion on whether to mention the word 
CF, or anything suggesting it, is not consensual; 
the presence of the child: we recommend receiving the two parents with their 
chi ld to make the announcement to all concerned. However, the babies 
included in our study were rarely present when the diagnosis was announced; 
the quantity of information given : the announcer should be careful to give 
neither too much nor too little information. However, parents said they 
received too much information about CF during the first meeting with the 
physician. 
We don't have comparative results for a number of recommendations (e.g.: about 
the involvement of the general practitioner), so we need to study these items further. 
The next step is to evaluate the impact of the guidelines upon the announcement 
pr ccedures used today. 
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Search for biomarkers in cystic fibrosis (CF) using Matrix-Assisted 
Laser Desorption/Ionization (MALDI)-Time of Flight (TOF)-Mass 
Spectrometry (MS) 
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Aim. Proteomic analysis offers a powerful approach to identify disease associated 
proteins that can be usvxl as biomar ker s. The aim is to investigate he clinical util ity 
of pr oteomic profi l ing to examine pre analytical factors and to detect discrimat ory 
markers of CE 
Methods. Blood collections were performed in 7 healthy subjects. Different ypes 
of collection tubes were tested for analysis of serum (St), EDTA or heparinazed 
(H) plasma (PI), and different imes of collection such as fasting (TO), lh  after 
breakfast (T1) or late in the afternoon (T2). Chromatography pre treatments using 
magnetic" beads (MB) were used: hydrophobic (HIC) and weak cationic interactions 
and metal chelation. Samples were analyzed by MALDI  TOF MS (AutoFlex, 
Bruker). 
Results. Mass spectra obtained with samples of Sr from controls showed more m/z 
fragments as compared to those of EDTA or H Pl. Us ing MB HIC pre treatment 
and considering 300 peaks detected in Sr with a signal:noise ratio>10, only 26+5% 
(mean+SD) of the peaks were observed in EDTA Pl mad 26+6% in H Pl. Detection 
of peaks was more important with Sr TO samples than those at T1 or T2. Clinical 
trial included TO Sr collection from CF patients. Sr pre treatment with HIC MB was 
used for the prel iminary esearch of potential CF biomarkers. Each mass spectrum 
from CF Sr was compared to normal profi l ing using a "gel based" presentation. 
Conclusions. The results show that the robustness of proteomic profi l ing depends 
to rigorous conditions of blood collection. Discrimatory peaks highlighted by the 
gel visualization, wi l l  further be tested in terms of util ity ha diagnosis, prognosis mad 
monitoring with large CF population. 
